Increased Risk of Severe COVID With Anti-B-Cell MS Drugs? Increased Risk of Severe COVID With Anti-B-Cell MS Drugs?

Concerns raised over an increased risk of severe COVID-19 outcomes in MS patients on anti-CD20 B-cell depleting drugs such as ocrelizumab and rituximab following presentation of new data.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news